Recent research has used mathematical models to find out when people are likely to experience a weight loss plateau on GLP-1 agonist drugs vs. bariatric surgery vs. dietary interventions.
Eli Lilly reported its phase 3 clinical trial data that showed showed significant reduction in sleep apnea symptoms in people who take Zepbound or Mounjaro.
A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms. Tirzepatide, the main ingredient in these medications, reduced symptom severity by nearly two-thirds. Around 20% of participants taking tirzepatide experienced weight loss.